DDF is involved in several drug discovery programs including finding new cures for prostate cancer, dendritic based cancer vaccines, osteoporosis and Alzheimer. Furthermore, the company is actively seeking for drugs to facilitate drug transport over the blood brain barrier. The company is affiliated with the research group of Ger Strous to develop drugs to alter the Growth Hormone (GHR) metabolism in order to improve the quality of life in patients with serious diseases including cancer and AIDS and aging.
Role in RUBICON:
In close collaboration with the research group of Ger Strous, DDF will collaborate to characterize the protein networks involved in GHR trafficking and degradation in order to find new therapeutic targets for drug development. Based on these targets DDF will develop screens to find drugs able to control GH-sensitivity in collaboration with Rubicon. Furthermore, the company will be involved in monitoring the scientific progress, intellectual property management and licensing efforts.